This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-10. (Cancelled)

11. (New) A pharmaceutical composition with an improved injection site toleration comprising a therapeutically effective amount of a neurokinin receptor (NK-1) antagonist with a pharmaceutically acceptable cyclodextrin.

12. (New) A pharmaceutical composition according to Claim 11 wherein the antagonist is selected from the group consisting of piperazine compounds, spiro-substituted azacycles, dialkyline piperadino compounds, trypthophan urea, polycyclic amine compounds, substituted arylaliphatic compounds, aromatic amine compounds, quaternary ammonium salts or aromatic amine compounds, aryl-substituted heterocycles, polycyclicamine compounds, substituted aryl piperazines, carboxamide derivatives, and bis-piperadinyl non-peptidal compounds, or salts thereof.

13. (New) The pharmaceutical composition of Claim 12 wherein the NK-1 antagonist is a compound comprising Formula I,



I

or pharmaceutically acceptable salt or prodrug thereof, wherein R^2 is selected from the group consisting of methyl, ethyl, isopropyl, *sec*-butyl and *tert*-butyl.

14. (New) A pharmaceutical composition according to claim 13 wherein the compound comprising Formula I is a compound comprising Formula Ia,



Ia

or a pharmaceutically acceptable salt or prodrug thereof.

15. (New) A pharmaceutical composition according to Claim 13 wherein the therapeutically effective amount of the NK-1 antagonist is 0.01 mg/kg to 100 mg/kg of a patient's body weight.

16. (New) A pharmaceutical composition according to Claim 14 wherein the therapeutically effective amount of the NK-1 antagonist is 0.01 mg/kg to 100 mg/kg of a patient's body weight.

17. (New) A pharmaceutical composition according Claim 15 wherein the therapeutically effective amount of the NK-1 antagonist is 0.10 mg/kg to 10 mg/kg of a patient's body weight.

18. (New) A pharmaceutical composition according Claim 16 wherein the therapeutically effective amount of the NK-1 antagonist is 0.10 mg/kg to 10 mg/kg of a patient's body weight.

19. (New) The pharmaceutical composition according to Claim 12 wherein said cyclodextrin is selected from β-cyclodextrin, sulfobutylether cyclodextrin, hydroxypropyl cyclodextrin, hydroxyethyl cyclodextrin, glucosyl cyclodextrin, maltosyl cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, hydroxyethyl-β-cyclodextrin, dihydroxypropyl-β-cyclodextrin, glucosyl-β-cyclodextrin,

diglycosyl-β-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotrialsyl-β-cyclodextrin, maltotrialsyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, cyclodextrin derivatives, various mixtures of cyclodextrin derivatives thereof, mixtures such as maltosyl-β-cyclodextrin/dimaltosyl-β-cyclodextrin, and any other similar cyclodextrin known to those of skill in the art.

20. (New) The pharmaceutical composition according to Claim 19 wherein the cyclodextrin is selected from β-cyclodextrin, hydroxypropyl β-cyclodextrin, sulfobutylether β-cyclodextrin or substituted cyclodextrins.

21. (New) The pharmaceutical composition according to Claim 20 wherein the cyclodextrin is about 2% to about 40% of the composition.

22. (New) The pharmaceutical composition according to Claim 21 wherein the cyclodextrin is about 4% to about 20% of the composition.

23. (New) The pharmaceutical composition according to Claim 22 wherein the cyclodextrin is about 5% to about 10% of the composition.

24. (New) The pharmaceutical composition according to Claim 20 for use as a medicament.

25. (New) The pharmaceutical composition of (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine and a pharmaceutically acceptable cyclodextrin where said cyclodextrin is selected from the group consisting of β-cyclodextrin, hydroxypropyl β-cyclodextrin, sulfobutylether β-cyclodextrin or substituted cyclodextrins .

26. (New) The use of a composition according to Claim 11 in the manufacture of a medicament for the treatment of a disease for which a NK-1 antagonist is indicated.

27. (New) A method for the treatment of a disease for which a NK-1 antagonist is indicated in mammals comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition of Claim 11.